Saving changes...

Done

Error

Metastatic Colorectal Cancer: Targeting What Pharmacists Need to Know

Metastatic Colorectal Cancer: Targeting What Pharmacists Need to Know

Metastatic Colorectal Cancer: Targeting What Pharmacists Need to Know

Jane E. Rogers, PharmD, BCOP
Jane E. Rogers, PharmD, BCOP
on behalf of Postgraduate Healthcare Education, LLC

FREE
FREE
FREE

FREE
FREE
FREE

null FREE
FREE
FREE
null FREE
FREE
FREE
Normal Price: FREE FREE

Review:

Launch date: 13 Mar 2017
Expiry Date:

Last updated: 15 Mar 2017

Reference: 172093

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

You have null days left.

Description

Approximately 60% to 70% of patients with metastatic colorectal cancer (mCRC) who undergo successful liver resection will go on to develop further metastatic disease resulting in death within 2 years of surgery. For these patients, and for those with unresectable mCRC, chemotherapy using cytotoxic and/or targeted therapies are the only remaining treatment options. The primary mechanisms of action for targeted therapies include angiogenesis inhibition, via blocking vascular endothelial growth factor (VEGF) activity, or epidermal growth factor receptor (EGFR) inhibition. This comprehensive archived webcast will provide the most current science on the mechanisms of action of targeted therapy agents, patient populations that will and will not respond to treatment, the ability to differentiate the features of both class and mechanistic effects, and the knowledge to interpret survival data from clinical trials. Additional topics to be covered include: how to best premedicate patients if needed, effective strategies to monitor patients for drug interactions and treatment adherence, methods to guide the timing of continued therapy, and appropriate measures to prevent and manage side-effects and toxicities.

Objectives

Objectives
Upon the conclusion of this activity, the participant should be able to:

-DESCRIBE place in therapy for mCRC agents.
-IDENTIFY the mechanisms of action of current therapies for mCRC.
-FORMULATE strategies to overcome barriers to accessibility and adherence to mCRC therapies.
-DEMONSTRATE approaches to effectively manage both side-effects and toxicity reactions.
Jane E. Rogers, PharmD, BCOP

Author Information Play Video Bio

Jane E. Rogers, PharmD, BCOP
on behalf of Postgraduate Healthcare Education, LLC

Jane E. Rogers, PharmD, BCOP Clinical Pharmacy Specialist GI Medical Oncology University of Texas MD Anderson Cancer Center Houston, Texas

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Accreditation Council for Pharmacy Education (ACPE)
  • 1.50 Hours -
    Exam Pass Rate: 75
    -
    Reference: 0064-0000-16-204-H01-P

Faculty and Disclosures

Additional Contributors

null

Conflicts Declared

Conflicts of Interest declaration by Author:

null

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error